17 closest matches · ranked by relevance
Richter's Transformation · Leukemia
Primary: Maximum Total Tolerated Dose (MTD) of Daily Combination Fludarabine 30 mg/m^2 and Cytarabine 500 mg/m^2 Among 3 Dose Levels (Dose Level 1: 2 Days, Dose Level 2: 3 Days…
Leukemia
Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) Receiving TST and I 131 TST With a Response >=30 Days Versus Par. With a Response >=30 Days After Their Last Qualifying Chemotherapy…
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants
Anemia
Primary: Hemoglobin Concentration at Monthly Intervals — 11.27; 11.26; 11.19; 11.14 g/dL
Lymphoma, Non-Hodgkin
Primary: Number of Participants Who Received the Therapeutic Dose at the Seven Clinical Research Sites — 7; 8; 8; 5 participants
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Primary: Objective Response Rate (CR + PR) — 46.7 percentage of participants
Leukemia · Lymphoma
Primary: Overall Survival at 1 Year — 90 percentage of participants
Lymphoma · Hodgkin's Disease
Primary: Disease-free Survival — 76; 88; 70 percentage of participant